The latest update is out from YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H ( (HK:1558) ).
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. reported a significant decline in financial performance for the year ending December 31, 2024, with a 40.84% decrease in revenue and a 75.78% drop in profit attributable to equity shareholders. Despite these challenges, the company has made strides in expanding its product pipeline, particularly in the chronic disease and new drug sectors. The launch of self-developed insulin products and the approval of innovative drugs like Olorigliflozin and Encofosbuvir Tablets mark significant milestones, enhancing the company’s competitive position in the pharmaceutical industry.
More about YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. is a pharmaceutical company based in China, focusing on the development and sale of innovative drugs. Its primary products include the Kewei brand for influenza treatment, insulin series for chronic diseases, and various innovative drugs for diabetes and hepatitis C treatment.
YTD Price Performance: 0.42%
Average Trading Volume: 3,060,573
Technical Sentiment Signal: Hold
Current Market Cap: HK$8.45B
Learn more about 1558 stock on TipRanks’ Stock Analysis page.